Singleron Biotechnologies

The page describes how data generation strategies—such as perturbation screens and multi-omics—enhance AI virtual cell model accuracy.

What is AI Virtual Cell (AIVC), why is it important, and what are its limitations and future development trends

Go beyond standard scRNA-seq: Analyze gene expression, non-coding RNAs, alternative splicing, and mutation information from every cell.

FocuSCOPE 16S is a new single cell technology designed to overcome limitations in studying intracellular bacteria in tumor microenvironments.

The page offers a form to request a quote for Single Cell’s single-cell solutions.

To learn more about our latest promotions in bulk mRNA sequencing services, feel free to contact us at info@singleron.bio.

Microwell vs droplet scRNA-seq: compare Singleron GEXSCOPE v3 and 10x Genomics GEM-X v4 on mouse bone marrow for quality, recovery, and sensitivity.

Singleron Biotechnologies provides solutions for single cell sequencing technologies to clinicians and researchers.

The page lists Single Cell’s product portfolio for single-cell sequencing workflows.

The page promotes Single Cell’s patented full-spectrum single-cell sequencing solutions.

Singleron Biotechnologies acquires Proteona Pte. Ltd., a Singapore-based precision medicine company specializing in single-cell biomarker discovery services for global translational and clinical researchers. The move expands Singleron’s capabilities in single-cell multi-omics technologies and clinical applications.

Mar 2022PR NewswireNews article

Arch Venture invests in 28 biotech startups across funding rounds from $3.8 million to $500 million. The firm backs early-stage companies through seed rounds and later-stage ventures in Series B financings. These investments span a diverse portfolio of biotech innovations.

Dec 2021Business InsiderNews article

Singleron Biotechnologies secures an oversubscribed **$100M Series B round**, led by Lake Bleu Capital, Firstred Capital, and MSA Capital alongside returning backers. The biotech firm applies single-cell multi-omics technologies to clinical applications, drug development, and health management. Investors include Sherpa Healthcare Partners, Lilly Asia Ventures, and ARCH Venture Partners.

Nov 2021SingleronNews article